Conditions That Amplify Women’s Cardiovascular Risk: Diabetes, Autoimmune Disease, Inflammation, and Postmenopausal Hypertension

Conditions That Amplify Women’s Cardiovascular Risk: Diabetes, Autoimmune Disease, Inflammation, and Postmenopausal Hypertension

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief

This article is about a category of conditions that quietly amplify cardiovascular risk in women more than they do in men — and that the conventional cardiovascular risk calculator was not built to capture. Diabetes. Autoimmune diseases like rheumatoid arthritis and lupus. Chronic systemic inflammation, including from HIV. Hypertension that emerges after menopause. Each is common in women, often managed by clinicians who are not cardiologists, and often treated as separate from cardiovascular care. The result is that women with these conditions sometimes carry meaningfully higher cardiovascular risk than their numbers suggest.

For the same diagnosis, women’s relative cardiovascular risk is larger than men’s. Type 2 diabetes raises a woman’s relative risk of coronary heart disease nearly threefold (RR 2.82) versus roughly twofold in men (RR 2.16) — a 44 percent greater excess. (1) Rheumatoid arthritis carries 50 percent excess cardiovascular mortality, with CVD accounting for 40 to 50 percent of deaths in established disease. (5) Lupus, HIV, and postmenopausal hypertension all amplify risk more in women than the calculator captures. (6,8,10) The 2019 ACC/AHA primary prevention guideline addresses these gaps through the risk-enhancing factors framework. (10) This article walks through each amplifier, names the specific treatments that reduce cardiovascular events, and tells you what your visits should cover.

Why These Conditions Affect Women Differently

The conventional cardiovascular risk factors — hypertension, abnormal cholesterol, diabetes, smoking, obesity, physical inactivity — affect both sexes. The contemporary evidence increasingly shows that several of these factors produce larger relative increases in cardiovascular risk in women than in men. This is not a mathematical artifact of women’s lower baseline rates. It is a real biological and clinical finding: women’s vascular systems respond differently to the same risk factor exposure.

The reasons are several, and they likely operate together.

Women’s vascular biology before menopause is partly protective, and these conditions erode that protection disproportionately. Premenopausal women have lower baseline rates of cardiovascular disease than age-matched men, attributable in part to estrogen-mediated vascular effects discussed in earlier articles. Diabetes, chronic inflammation, and autoimmune disease attenuate or eliminate this relative advantage — exposing women to coronary risk profiles that look more like the higher-risk male profile, sometimes at younger ages than would otherwise be expected.

Women with these conditions accumulate more cardiovascular risk factors alongside them. Women with diabetes are more likely than men with diabetes to also have hypertension, dyslipidemia, and central obesity. The cardiovascular signal from clustered risk factors is multiplicative rather than additive, and the clustering itself contributes to the sex difference. (1)

Some risk factors affect the vascular wall more strongly in women. Mechanistic studies suggest that insulin resistance and chronic inflammation produce greater impairments in endothelial function — the regulation of blood vessel tone and clotting tendency — in women than in men. The evidence on this point is suggestive rather than definitive, but the direction is consistent.

Sex-specific factors interact with general amplifiers. The factors discussed in earlier articles in this series — pregnancy history, menopause timing, hormonal contraception exposure, autoimmune predisposition — compound the effect of these general amplifiers. A woman with both an adverse pregnancy outcome history and diabetes carries higher cardiovascular risk than either condition alone would predict.

One factor that does not substantially explain the sex difference is differential pharmacotherapy. The Peters 2014 meta-analysis explicitly concluded that sex disparities in diabetes prescribing are unlikely to explain much of the excess cardiovascular risk in women. (1) The sex difference is biological more than it is therapeutic — though therapeutic optimization remains essential.

Diabetes

The cardiovascular implications of diabetes are well established: diabetes increases the risk of coronary heart disease, stroke, heart failure, and cardiovascular mortality in both sexes. What is less widely appreciated is that the excess risk is consistently and meaningfully greater in women.

The Headline Numbers

The 2014 meta-analysis by Peters and colleagues, published in Diabetologia, pooled data from 64 prospective cohort studies including 858,507 individuals and 28,203 incident coronary heart disease events. (1) The pooled relative risk of coronary heart disease associated with diabetes (versus no diabetes) was 2.82 (95% CI 2.35–3.38) in women and 2.16 (95% CI 1.82–2.56) in men. The ratio of these relative risks — a measure of how much greater the diabetes-attributable cardiovascular risk is in women than in men — was 1.44 (95% CI 1.27–1.63).

For the same diabetes diagnosis, women’s relative risk of coronary heart disease nearly triples (multiplies by 2.8), while men’s only doubles (multiplies by 2.2). The diabetes effect on coronary risk is meaningfully larger in women. (1)

A companion meta-analysis by the same group, published in The Lancet the same year, demonstrated a similar pattern for stroke: women with diabetes had a 27 percent greater excess stroke risk than men with diabetes (RRR 1.27, 95% CI 1.10–1.46). (2)

Diabetes Substantially Reduces the Female Cardiovascular Advantage

One of the most important observations in this literature is that diabetes appears to attenuate, and in some measures essentially eliminate, the cardiovascular advantage that women typically have over men of the same age. A woman without diabetes is at lower cardiovascular risk than a man of the same age. A woman with diabetes carries cardiovascular risk that approaches that of a man with diabetes. Diabetes does not just add risk for a woman — it changes which risk profile she belongs in.

The mechanisms underlying this sex difference are not fully established but include several converging factors. Women with diabetes tend to develop more adverse lipid patterns than men with diabetes — including higher triglycerides and a shift toward smaller, denser LDL particles, both associated with elevated cardiovascular risk. Women with diabetes are more likely than men with diabetes to also have hypertension, central obesity, and abnormal cholesterol, and the combined burden multiplies cardiovascular risk. Some mechanistic studies suggest that insulin resistance and hyperglycemia produce greater endothelial dysfunction in women than in men, though the evidence on magnitude is still evolving.

Treatments That Specifically Reduce Cardiovascular Risk

The diabetes-cardiovascular conversation has been transformed in the past decade by two drug classes that demonstrably reduce cardiovascular events in addition to controlling blood glucose.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) were originally developed as glucose-lowering medications. The EMPA-REG OUTCOME trial (Zinman et al., 2015, New England Journal of Medicine) showed that empagliflozin reduced the primary composite cardiovascular outcome — cardiovascular death, nonfatal MI, or nonfatal stroke — by 14 percent in patients with type 2 diabetes and established cardiovascular disease (HR 0.86, 95% CI 0.74–0.99). The secondary breakdowns were even more striking: cardiovascular death was reduced by 38 percent (HR 0.62), all-cause mortality by 32 percent (HR 0.68), and hospitalization for heart failure by 35 percent (HR 0.65) — effects larger than glucose control alone could explain. (3) Subsequent trials confirmed these benefits across the SGLT-2 inhibitor class. Major guidelines now formally recommend SGLT-2 inhibitors for patients with type 2 diabetes who have, or are at high risk of, cardiovascular disease.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, others) have similarly demonstrated cardiovascular benefit. The LEADER trial (Marso et al., 2016, New England Journal of Medicine) evaluated liraglutide in 9,340 patients with type 2 diabetes and high cardiovascular risk and found a 13 percent reduction in the primary composite cardiovascular outcome (HR 0.87, 95% CI 0.78–0.97), a 22 percent reduction in cardiovascular death (HR 0.78), and a 15 percent reduction in all-cause mortality (HR 0.85). (4) SUSTAIN-6 (semaglutide) and REWIND (dulaglutide) confirmed cardiovascular benefit across the class. GLP-1 receptor agonists are formally recommended for patients with type 2 diabetes and atherosclerotic cardiovascular disease.

The practical implication for a woman with type 2 diabetes is direct. The choice of diabetes medication is not just a glycemic decision. It is also a cardiovascular decision. If you have type 2 diabetes and have not been offered an SGLT-2 inhibitor or a GLP-1 receptor agonist — particularly if you have established cardiovascular disease, heart failure, kidney disease, or multiple cardiovascular risk factors — that is a reasonable conversation to raise with your diabetes care team or cardiologist. These medications carry their own side effects and contraindications, but for many women with type 2 diabetes they meaningfully reduce cardiovascular events in addition to controlling blood sugar.

A woman with diabetes warrants a cardiovascular conversation with the same intensity it would receive in a man with diabetes — sometimes more. The historical tendency to under-treat cardiovascular risk factors in women extends into the diabetic population, where the cost of under-treatment is higher than it is in men.

Autoimmune Diseases

Several autoimmune diseases occur substantially more often in women than in men and carry well-documented cardiovascular risk that the conventional cardiovascular framework has historically under-addressed.

Rheumatoid Arthritis

Rheumatoid arthritis is approximately two to three times more common in women than in men. Cardiovascular disease is the leading cause of premature mortality in rheumatoid arthritis, accounting for approximately 40 to 50 percent of deaths in established disease.

A 2008 meta-analysis by Avina-Zubieta and colleagues pooled data from 24 observational studies comprising 111,758 patients and 22,927 cardiovascular events. The pooled standardized mortality ratio for cardiovascular causes was 1.50 (95% CI 1.39–1.61) — a 50 percent increased risk of cardiovascular death compared with the general population. Ischemic heart disease mortality was elevated by 59 percent (SMR 1.59) and cerebrovascular mortality by 52 percent (SMR 1.52). (5)

The mechanisms include chronic systemic inflammation accelerating atherosclerosis (the same inflammatory cytokines that drive joint damage in rheumatoid arthritis — TNF-α, IL-6, others — also drive vascular inflammation, plaque formation, plaque vulnerability, and endothelial dysfunction), risk factor clustering, and treatment effects that are both protective and adverse.

Disease-modifying antirheumatic drugs (DMARDs) — particularly methotrexate — appear to reduce cardiovascular risk in rheumatoid arthritis. The mechanism is most likely through controlling RA disease activity rather than a general anti-inflammatory effect on the vasculature. The CIRT trial (Ridker et al., 2019, New England Journal of Medicine) showed that low-dose methotrexate in patients with cardiovascular disease but without RA did not reduce cardiovascular events. (11) The cardiovascular benefit of methotrexate in RA appears to be specifically a benefit of disease control. Corticosteroids, on the other hand, can increase cardiovascular risk through effects on blood pressure, lipids, and glucose, particularly with long-term use.

The contemporary joint guidance from rheumatology and cardiology societies recommends that cardiovascular risk assessment and risk factor management in rheumatoid arthritis should be more aggressive than in the general population. Controlling disease activity is itself a cardiovascular intervention.

Systemic Lupus Erythematosus

Systemic lupus erythematosus is approximately nine times more common in women than in men. Cardiovascular disease is a leading cause of mortality in lupus, with premature atherosclerosis far exceeding what conventional risk factors would predict.

The landmark study by Manzi and colleagues in 1997, published in the American Journal of Epidemiology, examined cardiovascular event rates in 498 women with lupus and compared them with the Framingham Offspring Study. The finding was striking: women with lupus aged 35 to 44 had approximately a 50-fold higher rate of myocardial infarction than women of the same age in Framingham (rate ratio 52.4, 95% CI 21.6–98.5). (6) The relative elevation declined with age but remained significant across the age range.

Two qualifications matter. The 50-fold figure is the headline number from a 1997 single-center cohort. Lupus care has improved substantially since — with better immunosuppression, attention to disease activity monitoring, and explicit cardiovascular risk factor management — and more recent multicenter cohorts have typically shown smaller (though still meaningfully elevated) cardiovascular risk in young women with lupus. The clinical message has not changed: lupus is associated with premature cardiovascular disease that far exceeds what conventional risk factors alone predict. The magnitude in any individual woman depends on her disease severity, disease control, antiphospholipid antibody status, and conventional risk factor profile.

The mechanisms include chronic immune-mediated inflammation, autoantibody-mediated endothelial injury (particularly when antiphospholipid antibodies are present), risk factor clustering, treatment effects (particularly long-term corticosteroid use), and possibly direct involvement of vasculature by the lupus disease process.

Contemporary guidance for women with lupus emphasizes aggressive cardiovascular risk factor management across the disease course — not only after a cardiovascular event has occurred. Blood pressure, cholesterol, and weight management; smoking cessation; and consideration of low-dose aspirin in selected high-risk patients are all part of contemporary lupus care.

Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) deserves specific attention because of its direct cardiovascular consequences. APS is an autoimmune condition characterized by antibodies against phospholipid-binding proteins that produce a strong tendency to form blood clots — both in the arteries (causing strokes, heart attacks, and other arterial events) and in the veins (causing deep vein thrombosis and pulmonary embolism). It is also a leading cause of recurrent pregnancy loss and preeclampsia, which connects it to the reproductive history conversation covered in Article 3 of this series.

APS causes cardiovascular events through hypercoagulability — a tendency to form clots in otherwise reasonable-looking blood vessels — rather than through the standard atherosclerotic plaque-and-rupture mechanism. This is a different cardiovascular pathway and has different treatment implications. The cornerstone of APS treatment in patients who have had a thrombotic event is long-term anticoagulation, not the antiplatelet plus statin approach that dominates standard cardiovascular care.

APS can be primary (occurring on its own) or secondary (occurring alongside another autoimmune disease, most commonly lupus). The presence of antiphospholipid antibodies, even without the full clinical syndrome, warrants a cardiovascular risk discussion calibrated to the antibody profile and clinical context.

Other Autoimmune Conditions

Several other autoimmune diseases carry varying degrees of cardiovascular risk amplification:

• Psoriasis and psoriatic arthritis — associated with elevated cardiovascular risk, particularly in moderate-to-severe disease
• Ankylosing spondylitis — elevated cardiovascular risk and altered vascular function
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) — elevated cardiovascular risk during active inflammation
• Sjögren’s syndrome — emerging evidence of cardiovascular risk amplification

The common thread is chronic systemic inflammation. Each condition’s specific risk profile is shaped by its particular pathophysiology, disease activity, and treatment patterns.

Chronic Inflammation and Immune Activation

The thread connecting much of the previous discussion — rheumatoid arthritis, lupus, the other autoimmune diseases — is chronic inflammation. Chronic systemic inflammation contributes to cardiovascular risk even when a discrete autoimmune diagnosis is not present, and even when the immune activation comes from a different cause entirely, such as a chronic viral infection. Inflammation itself is part of the cardiovascular risk picture, independent of whether a specific inflammatory disease has been named.

The hs-CRP Signal

High-sensitivity C-reactive protein (hs-CRP) is the most widely studied blood biomarker of chronic systemic inflammation in cardiovascular risk assessment. Elevated hs-CRP — typically defined as values at or above 2 milligrams per liter on multiple measurements not associated with acute illness — has been associated with elevated cardiovascular risk in both sexes. Some studies suggest hs-CRP may have somewhat greater predictive value in women than in men, though the evidence on the magnitude of this sex difference is mixed.

The interpretation of hs-CRP requires care. Acute illness, infection, smoking, obesity, and several other factors elevate hs-CRP. Multiple values over time are more informative than a single measurement. The 2019 ACC/AHA primary prevention guideline supports the use of hs-CRP as a risk-enhancing factor when it is persistently elevated in the absence of acute illness, similar to the framing of adverse pregnancy outcomes and premature menopause discussed in earlier articles. (10) It is not used as a primary risk calculator input but as a modifier when the calculated risk falls in a borderline range and additional information would change the prevention plan.

The biological mechanism connecting chronic inflammation to cardiovascular events is well established. Inflammatory cells and signaling molecules participate in every stage of atherosclerotic disease — the formation and progression of plaque, plaque vulnerability and rupture, endothelial dysfunction, and the prothrombotic state. The inflammatory pathway is not separate from the conventional risk factor pathway. It is in many ways the substrate through which conventional risk factors exert their cardiovascular effects.

HIV Infection

HIV infection illustrates how chronic immune activation translates into elevated cardiovascular risk even in the absence of an autoimmune diagnosis. People living with HIV — even those with excellent virologic control on antiretroviral therapy — carry approximately a 1.5- to 2-fold higher risk of major adverse cardiovascular events compared with people without HIV. (8) The drivers are persistent immune activation and inflammation (despite suppressed viral load), traditional risk factor clustering, and, with older medication regimens, the metabolic effects of some antiretroviral medications.

A particularly important observation: the cardiovascular amplification of HIV is substantially larger in women than in men. In a large U.S. epidemiologic study by Triant and colleagues (2007), HIV-infected women had approximately a 3-fold higher adjusted relative risk of myocardial infarction compared with HIV-uninfected women, whereas HIV-infected men had approximately a 1.4-fold higher risk compared with HIV-uninfected men. (8) The mechanism for this sex difference is not fully established but likely involves greater immune activation in HIV-infected women — particularly after menopause — layered on top of the female-specific cardiovascular vulnerabilities discussed throughout this series.

Modern antiretroviral therapy is substantially more metabolically neutral than the older protease inhibitor regimens that produced most of the historical concerns about HIV medications. Modern integrase strand transfer inhibitors do not produce the lipid and glucose effects that defined the older regimens. The cardiovascular risk that persists despite excellent virologic control appears to be driven primarily by chronic inflammation and immune activation rather than by current treatment effects.

The most important recent development in this area is the REPRIEVE trial (Grinspoon et al., 2023, New England Journal of Medicine). REPRIEVE was a global primary prevention trial of more than 7,700 people living with HIV who had low-to-moderate baseline cardiovascular risk — that is, people who would not have been candidates for statin therapy under the conventional ASCVD risk thresholds. Pitavastatin reduced major adverse cardiovascular events by 35 percent compared with placebo. (9) This is the first major primary-prevention statin trial specifically in the HIV population, and it has changed clinical practice. The contemporary guidance is that statin therapy should be considered earlier in people living with HIV than the conventional ten-year risk thresholds would otherwise support, particularly in women, in whom the HIV cardiovascular amplification is larger.

The 2019 ACC/AHA primary prevention guideline lists HIV/AIDS as a risk-enhancing factor. (10) For a woman living with HIV, the cardiovascular risk assessment should explicitly incorporate her HIV status. The standard ten-year risk calculator likely understates her actual risk given the inflammatory burden of HIV, and the conversation about statin initiation should reflect REPRIEVE’s findings.

The Unifying Principle

Across this entire family of conditions — autoimmune diseases, chronic elevation of hs-CRP, chronic viral infections like HIV — chronic inflammation and immune activation function as cardiovascular risk amplifiers through shared biological pathways. Controlling the underlying immune activation, whether through DMARDs, antiretroviral therapy, or anti-inflammatory effects of lipid-lowering medications, is part of cardiovascular care. This principle is increasingly recognized across rheumatology, infectious disease, and cardiology, though its translation into routine practice remains uneven.

Hypertension After Menopause

Hypertension is one of the conditions where the standard cardiovascular conversation needs sex-specific calibration that contemporary care has been slow to fully incorporate.

A Sharp Postmenopausal Rise

Before menopause, women have lower hypertension prevalence than men of the same age. After menopause, hypertension prevalence rises steeply in women, and by approximately age 65 the female prevalence equals and then exceeds the male prevalence. By age 75, the female predominance is substantial — in some U.S. surveys, more than 75 percent of women over age 65 have hypertension.

The contributors to this postmenopausal hypertension include the loss of estrogen’s vasodilating effects, weight gain, increased salt sensitivity, and other age- and menopause-related changes. The effect tends to manifest most prominently as a rise in systolic blood pressure — the top number — which is the form of hypertension that carries the strongest cardiovascular signal in older adults.

Why This Matters: HFpEF

Beyond its conventional implications (stroke, coronary disease, kidney disease, atrial fibrillation), hypertension in women is among the leading drivers of a particular form of heart failure: heart failure with preserved ejection fraction (HFpEF) — alongside obesity, diabetes, and atrial fibrillation.

HFpEF is heart failure in which the heart’s main pumping chamber still squeezes normally but has become stiff and unable to relax and fill properly between beats. The result is shortness of breath with exertion, fatigue, and fluid retention — heart failure symptoms despite a normal-looking pumping function on ultrasound.

HFpEF is approximately twice as common in women as in men. It is the most common form of heart failure in women and accounts for approximately half of all heart failure cases overall. It is driven by hypertension, obesity, diabetes, atrial fibrillation, and other factors discussed in this article — a constellation that occurs disproportionately in postmenopausal women.

HFpEF is also the form of heart failure for which medical therapies have, until recently, been least effective. The EMPEROR-Preserved trial (Anker et al., 2021) and the DELIVER trial (Solomon et al., 2022) demonstrated that SGLT-2 inhibitors (empagliflozin and dapagliflozin respectively) reduce HFpEF hospitalizations and improve symptoms in patients with established HFpEF. (7) This has substantially changed the treatment picture, but HFpEF remains a condition where prevention — through aggressive blood pressure control, weight management, and metabolic risk factor management — matters enormously.

The Implication

The treatment of hypertension in women is well-supported by major trials and society guidelines, with the same antihypertensive classes effective in both sexes. The clinical issue is not whether to treat but whether the threshold is calibrated to the actual risk and whether treatment is adequately intensified to achieve guideline-recommended targets. In a postmenopausal woman with rising blood pressure, the question of treatment intensity should be informed by her full risk profile — including her menopause timing, pregnancy history, weight, glucose status, and inflammatory markers — not by the blood pressure number alone.

The Risk-Enhancing Factors Framework

A woman with any of the conditions discussed in this article has a cardiovascular risk profile that the conventional ten-year risk calculator may not fully capture. A woman with multiple of these conditions has a risk profile that the calculator is even more likely to underestimate, because the interactions between amplifiers are not always linear.

The 2019 American College of Cardiology and American Heart Association primary prevention guideline addresses this gap formally through the risk-enhancing factors framework — a list of conditions beyond the standard calculator inputs that may justify reclassifying a person’s cardiovascular risk category and altering the intensity of prevention. (10) Several of the conditions covered in this article are explicitly listed:

• Chronic inflammatory diseases including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis
• HIV/AIDS
• Persistently elevated high-sensitivity C-reactive protein (≥2.0 milligrams per liter)
• Metabolic syndrome
• Chronic kidney disease

The framework also includes several conditions covered in earlier articles in this series — premature menopause (Article 5) and adverse pregnancy outcomes including preeclampsia and gestational diabetes (Article 3) — which makes it particularly relevant to women’s cardiovascular care across the lifespan.

When a woman’s calculator-derived ten-year cardiovascular risk falls in a borderline range, the presence of one or more risk-enhancing factors can shift her into a higher-intensity prevention category. In practice, this often means: a lower threshold for starting a statin, more aggressive blood pressure targets, more intensive lifestyle counseling, consideration of coronary artery calcium scoring to refine risk further, and more frequent reassessment over time. The conversation with her clinician about whether risk-enhancing factors apply, and how they should modify her prevention plan, is what converts the framework into individualized care.

What Your Care Should Cover

If you have one of the conditions covered in this article — or several — the cardiovascular conversation is one to lean into rather than wait out.

Cardiovascular risk should be assessed actively, not assumed. Women with these amplifying conditions sometimes encounter clinical pathways that focus on the immediate disease (controlling blood sugar, controlling joint inflammation, controlling blood pressure) without explicitly converting that into a cardiovascular risk conversation. Asking your primary care doctor or specialist “Given this condition, what is my cardiovascular risk picture, and what should we be doing about it?” is reasonable and appropriate at any visit.

The right team may include several clinicians. A woman with diabetes and rheumatoid arthritis may have an endocrinologist, a rheumatologist, and a primary care doctor. None of these clinicians alone is responsible for the cardiovascular conversation. In practice, it often does not happen unless someone asks for it. A primary care physician or cardiologist who explicitly takes ownership of the cardiovascular risk picture across her conditions is a meaningful asset.

Specific medications can do double duty. SGLT-2 inhibitors and GLP-1 receptor agonists reduce cardiovascular events in addition to controlling blood sugar. Controlling RA disease activity (including with methotrexate) reduces cardiovascular risk in rheumatoid arthritis. Aggressive blood pressure control reduces both stroke and HFpEF risk. The choice of medication within a condition is often a cardiovascular choice as well.

Lifestyle measures are foundational, not optional. For each of the conditions in this article, attention to weight, physical activity, sleep, diet quality, and smoking has cardiovascular benefit that is independent of medication. These measures matter more, not less, when amplifying conditions are present.

Inflammation control is cardiovascular care. For women with rheumatoid arthritis, lupus, inflammatory bowel disease, or other inflammatory conditions, achieving and maintaining low disease activity is itself a cardiovascular intervention. Skipping medications, deferring rheumatology follow-up, or accepting persistent inflammation as “background noise” has cardiovascular consequences.

The risk-enhancing factors framework should be on the table. When a primary prevention conversation happens — about statins, blood pressure targets, or other preventive measures — knowing that your conditions are formally recognized as risk-enhancing factors gives you a framework for asking whether your current prevention intensity is calibrated correctly. The 2019 ACC/AHA guideline is the reference, and your clinician can locate where you sit within it.

Family conversations may come up. Many of the conditions in this article have familial components. Autoimmune diseases tend to cluster in families, type 2 diabetes has a strong hereditary component, and the premature cardiovascular disease seen in some of these conditions can occur across generations. When relevant, your team may discuss screening or earlier intervention for first-degree relatives.

The Bottom Line

For a woman with diabetes, autoimmune disease, chronic inflammation, postmenopausal hypertension, or HIV, the standard ten-year cardiovascular risk calculator is the starting point of the conversation — not its endpoint. The conditions in this article amplify cardiovascular risk in women in ways the calculator does not always capture, sometimes substantially. The 2019 ACC/AHA primary prevention guideline addresses the gap through the risk-enhancing factors framework, which formally recognizes that calculator output alone undercounts risk in women with these conditions.

Several specific actions follow from this. A woman with type 2 diabetes should know whether she is on a cardiovascular-protective diabetes medication (an SGLT-2 inhibitor or a GLP-1 receptor agonist), particularly if she has established cardiovascular disease, heart failure, or multiple risk factors. A woman with rheumatoid arthritis, lupus, or another autoimmune condition should know that controlling disease activity is itself a cardiovascular intervention — and that the cardiovascular risk assessment in her care should be more aggressive than in the general population. A woman living with HIV should know that the post-REPRIEVE guidance supports earlier statin consideration than the conventional ten-year risk thresholds would otherwise suggest. A postmenopausal woman with rising blood pressure should know that her treatment intensity should be calibrated to her full risk profile, including the pregnancy and menopause history that informs HFpEF risk, not to the blood pressure number alone.

The cardiovascular risk calculator gives the average woman an average answer. A woman with amplifying conditions is not the average woman. Her cardiovascular conversation should reflect that — and the framework that supports it exists in current guidelines. Using it is the action that converts a generic risk number into care that fits her actual trajectory.

---

Next: Article 10 closes this series with prevention and the long view — how the elements covered across the series come together into a cardiovascular framework calibrated to a woman’s biology, history, and life course.

---

Key Terms

Antiphospholipid syndrome (APS): An autoimmune condition characterized by antibodies against phospholipid-binding proteins, producing increased risk of arterial and venous thrombosis, recurrent pregnancy loss, and other complications. Associated with substantial cardiovascular risk.

GLP-1 receptor agonist: A class of injectable diabetes medications (liraglutide, semaglutide, dulaglutide, others) that mimic the hormone GLP-1, reducing blood glucose and appetite. Several agents in this class have been shown to reduce major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Heart failure with preserved ejection fraction (HFpEF): A form of heart failure in which the heart’s main pumping chamber still squeezes normally but has become stiff and unable to relax and fill properly between beats. Approximately twice as common in women as in men. Driven by hypertension, obesity, diabetes, and other factors that cluster in postmenopausal women.

High-sensitivity C-reactive protein (hs-CRP): A blood biomarker of systemic inflammation. Persistently elevated values (typically ≥2 milligrams per liter, on measurements not associated with acute illness) are associated with elevated cardiovascular risk and recognized as a risk-enhancing factor in the 2019 ACC/AHA primary prevention guideline.

Ratio of relative risks (RRR): In the diabetes-and-cardiovascular literature, the ratio of the diabetes-attributable cardiovascular risk in women to the diabetes-attributable risk in men. A women-to-men RRR above 1.0 indicates that diabetes is a stronger relative risk factor in women than in men.

REPRIEVE trial: A 2023 global randomized trial of more than 7,700 people living with HIV at low-to-moderate baseline cardiovascular risk. Pitavastatin reduced major adverse cardiovascular events by 35 percent compared with placebo. Changed clinical guidance toward earlier statin initiation in people living with HIV.

Rheumatoid arthritis (RA): A systemic autoimmune disease characterized by chronic inflammatory arthritis. Approximately three times more common in women than in men. Cardiovascular disease is the leading cause of premature mortality, accounting for 40 to 50 percent of deaths in established disease.

Risk-enhancing factor: A term in the 2019 American College of Cardiology and American Heart Association primary prevention guideline for conditions beyond the standard risk calculator inputs that may justify reclassifying cardiovascular risk and altering prevention intensity. Includes adverse pregnancy outcomes, premature menopause, chronic inflammatory diseases (rheumatoid arthritis, lupus, psoriasis), HIV/AIDS, persistently elevated hs-CRP, metabolic syndrome, chronic kidney disease, and several other conditions.

SGLT-2 inhibitor: A class of oral diabetes medications (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) that lower blood glucose by causing the kidneys to excrete more glucose in the urine. Shown in cardiovascular outcome trials to reduce cardiovascular death, heart failure hospitalization, and all-cause mortality in patients with type 2 diabetes and established cardiovascular disease.

Standardized mortality ratio (SMR): A measure of mortality in a particular group compared with the general population, adjusted for age and sex. An SMR of 1.50 means the group has 50 percent higher mortality than expected based on the general population rate.

Systemic lupus erythematosus (SLE): A systemic autoimmune disease that can involve nearly any organ system. Approximately nine times more common in women than in men. Associated with substantial premature cardiovascular risk, particularly in younger women.

Type 2 diabetes: The most common form of diabetes, characterized by insulin resistance and progressive beta-cell dysfunction. Confers greater relative cardiovascular risk in women than in men compared with the non-diabetic baseline.

References

1. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–1551.
2. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet.2014;383(9933):1973–1980.
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
5. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697.
6. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415.
7. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. (See also: Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098.)
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
9. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687–699.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232.
11. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events (CIRT). N Engl J Med. 2019;380(8):752–762.